Deep Learning Algorithm for Detecting Obstructive Coronary Artery Disease Using Fundus Photographs
Launched by YONG ZENG · Oct 22, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring how artificial intelligence (AI) can help detect heart disease by analyzing photographs of the back of the eye, known as fundus photographs. The researchers believe that by using deep learning—a type of AI that learns from data—they can identify signs of coronary artery disease (CAD) more quickly and accurately. This is important because currently, there are not many effective tools for early screening of heart disease, especially in places like China.
To participate in the trial, individuals need to be at least 18 years old, suspected of having coronary artery disease, and scheduled to undergo a specific heart test called coronary angiography. However, those who have already had certain heart procedures or other specific heart conditions may not be eligible. Participants will have their eye photographs taken, which will be used to help develop a model that could make diagnosing heart disease easier in the future. Before joining the study, everyone will be fully informed and must agree to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligible participants were ≥ 18 years of age, with clinically suspected CAD, and were scheduled for coronary angiography.
- Exclusion Criteria:
- • The exclusion criteria were as follows: (i) prior percutaneous coronary intervention (PCI); (ii) prior coronary artery bypass graft (CABG); (iii) other heart disease (e.g., congenital heart disease, valvular heart disease, or macrovascular disease); (iv) inability to have photographs taken; and (v) and a diagnosis of ST-segment elevation myocardial infarction (STEMI). Prior to the coronary angiography procedure, all eligible patients provided informed consent to participate in the study and to have their photographs used for research purposes.
About Yong Zeng
Yong Zeng is a dedicated clinical trial sponsor committed to advancing medical research and innovation. With a focus on developing novel therapies and improving patient outcomes, Yong Zeng collaborates with leading healthcare professionals and institutions to conduct rigorous clinical trials across various therapeutic areas. Their expertise encompasses the entire trial process, from study design and regulatory compliance to data analysis and reporting. By prioritizing ethical standards and patient safety, Yong Zeng aims to contribute significantly to the pharmaceutical and biotechnology sectors, ultimately enhancing the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, 北京, China
Beijing, , China
Patients applied
Trial Officials
Yong Zeng
Principal Investigator
Beijing An Zhen Hospital: Capital Medical University Affiliated Anzhen Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported